ACRV
ACRIVON THERAPEUTICS INC

1,195
Mkt Cap
$47.65M
Volume
830,822.00
52W High
$5.75
52W Low
$1.05
PE Ratio
-0.71
ACRV Fundamentals
Price
$1.49
Prev Close
$1.51
Open
$1.49
50D MA
$1.95
Beta
1.54
Avg. Volume
3.69M
EPS (Annual)
-$2.38
P/B
0.37
Rev/Employee
$0.00
$27.59
Loading...
Loading...
News
all
press releases
Acrivon Therapeutics Conference Highlights ACR-368 Phase 2B Data, 52% ORR in Serous Endometrial Cancer
Acrivon Therapeutics (NASDAQ:ACRV) hosted a webcast featuring a key opinion leader (KOL) panel focused on the company's ongoing ACR-368 registrational-intent Phase 2B study in endometrial cancer...
MarketBeat·3d ago
News Placeholder
More News
News Placeholder
Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Sees Large Drop in Short Interest
Acrivon Therapeutics, Inc. (NASDAQ:ACRV - Get Free Report) was the recipient of a significant drop in short interest in January. As of January 30th, there was short interest totaling 2,024,627...
MarketBeat·19d ago
News Placeholder
Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Sees Large Increase in Short Interest
Acrivon Therapeutics, Inc. (NASDAQ:ACRV - Get Free Report) was the target of a large growth in short interest in January. As of January 15th, there was short interest totaling 7,521,144 shares, a...
MarketBeat·29d ago
News Placeholder
Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Given Average Rating of "Moderate Buy" by Brokerages
Shares of Acrivon Therapeutics, Inc. (NASDAQ:ACRV - Get Free Report) have received a consensus rating of "Moderate Buy" from the seven analysts that are presently covering the company, MarketBeat.com...
MarketBeat·1mo ago
News Placeholder
Adam Levy Acquires 8,832 Shares of Acrivon Therapeutics (NASDAQ:ACRV) Stock
Acrivon Therapeutics, Inc. (NASDAQ:ACRV - Get Free Report) CFO Adam Levy bought 8,832 shares of the company's stock in a transaction on Wednesday, January 14th. The shares were acquired at an average...
MarketBeat·1mo ago
News Placeholder
Acrivon Therapeutics (NASDAQ:ACRV) CFO Adam Levy Acquires 8,832 Shares
Acrivon Therapeutics, Inc. (NASDAQ:ACRV - Get Free Report) CFO Adam Levy bought 8,832 shares of the firm's stock in a transaction on Wednesday, January 14th. The stock was bought at an average price...
MarketBeat·1mo ago
News Placeholder
Acrivon Therapeutics (NASDAQ:ACRV) CEO Peter Blume-Jensen Purchases 49,000 Shares
Acrivon Therapeutics, Inc. (NASDAQ:ACRV - Get Free Report) CEO Peter Blume-Jensen purchased 49,000 shares of the company's stock in a transaction that occurred on Wednesday, January 14th. The shares...
MarketBeat·1mo ago
News Placeholder
Acrivon Therapeutics (NASDAQ:ACRV) COO Eric Devroe Purchases 10,000 Shares
Acrivon Therapeutics, Inc. (NASDAQ:ACRV - Get Free Report) COO Eric Devroe acquired 10,000 shares of the business's stock in a transaction that occurred on Tuesday, January 13th. The shares were...
MarketBeat·2mo ago
News Placeholder
Acrivon Therapeutics (NASDAQ:ACRV) COO Purchases $17,200.00 in Stock
Acrivon Therapeutics, Inc. (NASDAQ:ACRV - Get Free Report) COO Eric Devroe bought 10,000 shares of the business's stock in a transaction that occurred on Tuesday, January 13th. The shares were...
MarketBeat·2mo ago
News Placeholder
Acrivon Stock Sinks 29% Despite Positive Phase 2b Endometrial Cancer Data
(RTTNews) - Acrivon Therapeutics, Inc. (ACRV) shares fell 28.71%, trading at $2.1044, down $0.8456, after the company reported updated Phase 2b clinical results for its lead candidate ACR-368 in...
Nasdaq News: Markets·2mo ago
<
1
2
...
>

Latest ACRV News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.